Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Self-Presentation01:25

Self-Presentation

325
Self-presentation is a fundamental aspect of social interaction, shaping both how others perceive individuals and how they view themselves. This dynamic process influences behaviors in various social settings, often leading people to adjust their appearance, speech, and demeanor to align with their desired identity. While self-presentation can be deliberate or unconscious, it plays a critical role in interpersonal relationships and self-perception.Forms of Self-PresentationSelf-presentation can...
325
Self-Presentation: Self-Monitoring and Self-Handicapping02:05

Self-Presentation: Self-Monitoring and Self-Handicapping

44.8K
People can go to great lengths to protect their self-image and present themselves in ways that they want others to see them. Sociologist Erving Goffman presented the idea that a person is like an actor on a stage. Calling his theory dramaturgy, Goffman believed that we use “impression management” to present ourselves to others as we hope to be perceived. Each situation is a new scene, and individuals perform different roles depending on who is present (Goffman, 1959). Think about...
44.8K
Strategies of Self-Presentation I: Strategic Self-Presentation01:12

Strategies of Self-Presentation I: Strategic Self-Presentation

229
Strategic self-presentation refers to individuals' intentional efforts to influence how others perceive them. This process is employed in various social and professional settings, such as job interviews, dating, politics, and legal contexts, where individuals seek to shape impressions to gain social or material advantages. While people generally present themselves in ways that align with their authentic characteristics, external factors, such as cognitive load, can hinder their ability to...
229
Processes of Self-Presentation01:29

Processes of Self-Presentation

254
Effective self-presentation is a central component of social interaction and identity construction. It relies on the dynamic processes of defining the situation and engaging in self-disclosure. These mechanisms help individuals navigate social context expectations and manage how others perceive them, fostering mutual understanding and relationship development.Defining the SituationSocial situations are shaped by collectively understood frames—a set of widely understood rules or...
254
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Current Trends in Nursing I01:28

Current Trends in Nursing I

5.5K
Current trends in nursing include:
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Targeted oncology·2026

Related Experiment Video

Updated: Feb 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Anusha Kalbasi1,2,3, Antoni Ribas4,3,5

  • 1Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 21, 2018
PubMed
Summary

A novel gene, MEX3B, mediates resistance to T-cell immunotherapy by regulating HLA-A. This finding highlights tumor-intrinsic antigen presentation as a critical factor and identifies MEX3B as a potential therapeutic target.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.6K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • T-cell immunotherapy has revolutionized cancer treatment.
  • Mechanisms of resistance, particularly those involving tumor-intrinsic factors, require further elucidation.
  • CRISPR-based screens have identified some resistance mediators, but a comprehensive understanding remains incomplete.

Purpose of the Study:

  • To identify novel mediators of resistance to T-cell immunotherapy.
  • To investigate the role of MEX3B in T-cell immunotherapy resistance.
  • To explore MEX3B as a potential therapeutic target.

Main Methods:

  • A gain-of-function kinome screen was employed to identify genes conferring resistance.
  • The function of MEX3B in regulating HLA-A expression was assessed.
  • The impact of MEX3B on T-cell immunotherapy efficacy was evaluated.

Main Results:

  • MEX3B was identified as a novel mediator of resistance to T-cell immunotherapy.
  • MEX3B was found to be a posttranscriptional regulator of HLA-A.
  • The study validated the importance of tumor-intrinsic antigen presentation in immunotherapy response.

Conclusions:

  • MEX3B represents a previously unrecognized molecular target for overcoming T-cell immunotherapy resistance.
  • Targeting MEX3B may enhance the efficacy of T-cell immunotherapy by improving antigen presentation.
  • Further research into MEX3B's role could lead to novel therapeutic strategies in oncology.